Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Obicetrapib - NewAmsterdam Pharma

X
Drug Profile

Obicetrapib - NewAmsterdam Pharma

Alternative Names: AMG 899; DEZ 001; obicetripib; TA-8995

Latest Information Update: 14 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mitsubishi Tanabe Pharma Corporation
  • Developer Amgen; Mitsubishi Tanabe Pharma Corporation; NewAmsterdam Pharma
  • Class Antidementias; Antihyperlipidaemics; Heterocyclic compounds; Quinolines; Small molecules
  • Mechanism of Action Cholesterol ester transfer protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Dyslipidaemias; Hyperlipoproteinaemia type IIa
  • Phase II Alzheimer's disease; Hypercholesterolaemia

Most Recent Events

  • 12 Jun 2024 NewAmsterdam has patent protection for "Salts of Obicetrapib and Processes for their Manufacture and Intermediates Thereof" in USA
  • 09 Apr 2024 NewAmsterdam Pharma completes enrolment in the Phase-III clinical trials in Dyslipidaemias (In adults, In the elderly, Treatment-experienced) in South Africa, Croatia, Georgia, Jordan, Latvia, United Kingdom, Poland, Netherlands, Japan, Italy, Israel, Germany, Slovakia, Spain, Hungary, Finland, Denmark, China, Czech Republic, Canada, Bulgaria, USA, Australia (PO) (NCT05202509) (EudraCT2021-005092-39)
  • 06 Apr 2024 Efficacy and adverse events data from phase-II ROSE2 trial in Dyslipidaemias (Adjunctive treatment, Combination therapy, Monotherapy) presented at the 73rd Annual Scientific Session of the American College of Cardiology (ACC-2024)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top